|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tuttle RM, Haddad RI, Ball DW, Byrd D,
Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, et al:
Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw.
12:1671–1680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Antonelli A, Fallahi P, Ferrari SM, Carpi
A, Berti P, Materazzi G, Minuto M, Guastalli M and Miccoli P:
Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed
Pharmacother. 62:559–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schlumberger M, Brose M, Elisei R,
Leboulleux S, Luster M, Pitoia F and Pacini F: Definition and
management of radioactive iodine-refractory differentiated thyroid
cancer. Lancet Diabetes Endocrinol. 2:356–358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haddad RI, Lydiatt WM, Ball DW, Busaidy
NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, et
al: Anaplastic thyroid carcinoma, version 2.2015. J Natl Compr Canc
Netw. 13:1140–1150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Durante C, Haddy N, Baudin E, Leboulleux
S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De
Vathaire F and Schlumberger M: Long-term outcome of 444 patients
with distant metastases from papillary and follicular thyroid
carcinoma: Benefits and limits of radioiodine therapy. J Clin
Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations in the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of
a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci USA. 105:pp. 3041–3046.
2008; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim KH, Kang DW, Kim SH, Seong IO and Kang
DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a
Korean population. Yonsei Med J. 45:818–821. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Namba H, Nakashima M, Hayashi T, Hayashida
N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and
Yamashita S: Clinical implication of hot spot BRAF mutation, V599E,
in papillary thyroid cancers. J Clin Endocrinol Metab.
88:4393–4397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sherman SI, Angelos P, Ball DW, Beenken
SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB,
et al: Thyroid carcinoma. J Natl Compr Canc Netw. 3:404–457.
2005.PubMed/NCBI
|
|
17
|
DeGroot LJ, Kaplan EL, McCormick M and
Straus FH: Natural history, treatment, and course of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sherman SI, Brierley JD, Sperling M, Ain
KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, et
al: Prospective multicenter study of thyroid carcinoma treatment:
Initial analysis of staging and outcome. National thyroid cancer
treatment cooperative study registry group. Cancer. 83:1012–1021.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanaka K, Sonoo H, Hirono M, Ohkubo S,
Nomura T, Ikeda M, Nakajima K and Kurebayashi J: Retrospective
analysis of predictive factors for recurrence after curatively
resected papillary thyroid carcinoma. Surg Today. 35:714–719. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mazzaferri EL and Jhiang SM: Long-term
impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ
and Qu JM: The BRAF mutation is predictive of aggressive
clinicopathological characteristics in papillary thyroid
microcarcinoma. Ann Surg Oncol. 17:3294–3300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y,
Zhang Y, Cheng W and Zhao W: Analysis of differential BRAF(V600E)
mutational status in high aggressive papillary thyroid
microcarcinoma. Ann Surg Oncol. 16:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brose MS, Cabanillas ME, Cohen EEW, Wirth
L, Sherman SI, Riehl T, Yue H and Sherman E: An open label,
multi-center phase 2 study of the BRAF inhibitor vemurafenib in
patients with metastatic or unresectable papillary thyroid cancer
(PTC) positive for the BRAF V600 mutation and resistant to
radioactive iodine (NCT01286753, NO25530). Eur J Cancer. 49
Suppl:S132013.
|
|
25
|
Dadu R, Shah K, Busaidy NL, Waguespack SG,
Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI and
Cabanillas ME: Efficacy and tolerability of vemurafenib in patients
with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson
cancer center off label experience. J Clin Endocrinol Metab.
100:E77–E81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Falchook GS, Millward M, Hong D, Naing A,
Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis
M, et al: BRAF inhibitor dabrafenib in patients with metastatic
BRAF-mutant thyroid cancer. Thyroid. 25:71–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Murphy DA, Makonnen S, Lassoued W, Feldman
MD, Carter C and Lee WM: Inhibition of tumor endothelial ERK
activation, angiogenesis, and tumor growth by sorafenib
(BAY43-9006). Am J Pathol. 169:1875–1885. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lyons JF, Wilhelm S, Hibner B and Bollag
G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer.
8:219–225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hyman DM, Puzanov I, Subbiah V, Faris JE,
Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, et al:
Vemurafenib in multiple nonmelanoma cancers with BRAF V600
mutations. N Engl J Med. 373:726–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Montero-Conde C, Ruiz-Llorente S,
Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA,
Rosen N and Fagin JA: Relief of feedback inhibition of HER3
transcription by RAF and MEK inhibitors attenuates their antitumor
effects in BRAF-mutant thyroid carcinomas. Cancer Discov.
3:520–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prahallad A, Sun C, Huang S, Di
Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A
and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E)
inhibition through feedback activation of EGFR. Nature.
483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ribeiro FR, Meireles AM, Rocha AS and
Teixeira MR: Conventional and molecular cytogenetics of human
non-medullary thyroid carcinoma: Characterization of eight cell
line models and review of the literature on clinical samples. BMC
Cancer. 8:3712008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mercer KE and Pritchard CA: Raf proteins
and cancer: B-Raf is identified as a mutational target. Biochim
Biophys Acta. 1653:25–40. 2003.PubMed/NCBI
|
|
35
|
Baitei EY, Zou M, Al-Mohanna F, Collison
K, Alzahrani AS, Farid NR, Meyer B and Shi Y: Aberrant BRAF
splicing as an alternative mechanism for oncogenic B-Raf activation
in thyroid carcinoma. J Pathol. 217:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Byeon HK, Na HJ, Yang YJ, Kwon HJ, Chang
JW, Ban MJ, Kim WS, Shin DY, Lee EJ, Koh YW, et al: c-Met-mediated
reactivation of PI3K/AKT signaling contributes to insensitivity of
BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Mol Carcinog.
55:1678–1687. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sos ML, Levin RS, Gordan JD, Oses-Prieto
JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F,
Bandyopadhyay S and Shokat KM: Oncogene mimicry as a mechanism of
primary resistance to BRAF inhibitors. Cell Rep. 8:1037–1048. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Frasca F, Vella V, Nicolosi ML, Messina
RL, Gianì F, Lotta S, Vigneri P, Regalbuto C and Vigneri R: Thyroid
cancer cell resistance to gefitinib depends on the constitutive
oncogenic activation of the ERK pathway. J Clin Endocrinol Metab.
98:2502–2512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Danysh BP, Rieger EY, Sinha DK, Evers CV,
Cote GJ, Cabanillas ME and Hofmann MC: Long-term vemurafenib
treatment drives inhibitor resistance through a spontaneous KRAS
G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Oncotarget. 7:30907–30923. 2016. View Article : Google Scholar : PubMed/NCBI
|
